Last reviewed · How we verify
Human FGF-1
At a glance
| Generic name | Human FGF-1 |
|---|---|
| Sponsor | Zhittya Genesis Medicine, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome (NA)
- Intranasal Human FGF-1 for Subjects With Parkinson's Disease (PHASE1)
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease (PHASE1, PHASE2)
- Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease (PHASE2)
- FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers (PHASE1)
- Safety Study of Topical Human FGF-1 for Wound Healing (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human FGF-1 CI brief — competitive landscape report
- Human FGF-1 updates RSS · CI watch RSS
- Zhittya Genesis Medicine, Inc. portfolio CI